drugset / Trial / NCT04429451

PSMA-specific CAR-T Cell Therapy

NCT04429451 ↗

Phase 1/2 Recruiting 100 enrolled Shenzhen Geno-Immune Medical Institute
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.

Timeline

Start
2026-06-01
Primary completion
2029-10-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 4SCAR-PSMA T cells Cell therapy 1e+06 cells/kg Intravenous

Indications

No indication recorded.